European public procurement and grants data from official registers · Data as of 18 November 2026; updated daily.

Tenders

Oncology drug tenders in Spain

Oncology drug tenders in Spain: 723 listed on GranTender since 2024; 2 open now. The median awarded contract value is about €100,000 (1,407 contracts with a stated value). Buyers with the most tenders: Consellería de Sanidade- SERGAS (114), Hospital Universitario Principe de Asturias (72) and Gestió Pius Hospital de Valls, SAM (54); suppliers with the most contract awards: Janssen Cilag, S.A. (128), PFIZER, S.L.U. (85) and Roche Farma, S.A. (84). Sources: PLACSP, Registre públic de contractes de Catalunya (RPC) — Catalan public contracts register, open data (Generalitat) and TED. In 2025 the median contract value was €41,000; 32% of contracts drew a single bid (2.6 bids on average). Data as of 18 November 2026; updated daily.

Tenders
723
Open tenders
2
Awards
1,965
Awarded value awarded
€1,551,962,824
Awarded value contract
€1,037,876
Awarded value framework ceiling
€755,144,999
Median contract value awarded
≈ €100,000
Median contract value framework ceiling
≈ €160,000
Median contract value contract
≈ €18,000
Average bids per contract
3.0
Tenders in 2025
169 -31% on 2024

Median: contracts with a stated value, rounded. Average bids: contracts where the number of bids is published.

Value kinds: awarded — the value in the award decision; contract — the value of the signed or amended contract; paid — the amount actually paid; framework ceiling — the maximum of a framework agreement, given with every winner, not money spent. Different kinds are never added together.

Open tenders

Latest tenders

TenderBuyerEstimated valueStatusPublished
Suministro de medicamentos biológicos con biosimilares, lote 11 Tocilizumab (vía parenteral subcutánea), para el Servicio de Farmacia del Hospital Clínico Universitario de Valladolid, basado del Acuerdo Marco 2025/034 celebrado por el Instituto Nacional de Gestión Sanitaria (INGESA): Suministro respetuoso con el medio ambiente de medicamentos Biológicos con biosimilares.Gerencia de Atención Especializada Hospital Clínico Univ. de Valladolid€181,523Awarded17 November 2026
Suministro sucesivo de diversos medicamentos para el tratamiento del mieloma múltiple para el Área Sanitaria de FerrolServizo Galego de Saúde. Área Sanitaria de Ferrol€1,465,300Awarded17 November 2026
SUMINISTRO SUCESIVO DE MEDICAMENTOS DE INMUNOTERAPIA ONCOLÓGICA PARA LOS CENTROS HOSPITALARIOS EN EL ÁREA SANITARIA DE PONTEVEDRA E O SALNÉS.Xunta de Galicia/Conselleria de Sanidade/SERGAS/Área Sanitaria de Pontevedra e o Salnés€9,967,839Awarded17 November 2026
Suministro sucesivo de diversos medicamentos para el tratamiento del mieloma múltiple con destino al Área Sanitaria de Santiago de Compostela e Barbanza.Servicio Gallego de Salud. Área Sanitaria de Santiago de Compostela y Barbanza€7,423,975Awarded13 November 2026
EN La-ASF1-26-027. Contratación mediante Acuerdo Marco con varios empresarios de él suministro sucesivo de diversos medicamentos para él tratamiento de él mieloma múltiple para él Área Sanitario de FerrolConsellería de Sanidade- SERGAS—Awarded13 November 2026
Suministro de medicamentos para el Servicio de Farmacia del Hospital Universitario de Ceuta, mediante contrato basadoGerencia de Atención Sanitaria del Instituto Nacional de Gestión Sanitaria en Ceuta€63,270Awarded12 November 2026
Suministro de medicamentos para el Servicio de Farmacia del Hospital Universitario de Ceuta, mediante contrato basado.Gerencia de Atención Sanitaria del Instituto Nacional de Gestión Sanitaria en Ceuta€336,600Awarded12 November 2026
EN La-ASC1-26-063. Él suministro sucesivo de AXICABTAGEN CILOLEUCEL para tratamiento individual por paciente.Consellería de Sanidade- SERGAS—Awarded12 November 2026
Suministro de medicamentos para el Servicio de Farmacia del Hospital Universitario de Ceuta mediante contrato basado.Gerencia de Atención Sanitaria del Instituto Nacional de Gestión Sanitaria en Ceuta€85,423Awarded12 November 2026
Suministro de medicamentos exclusivos con principios activos belimumab, mepolizumab, niraparib y momelotinib del laboratorio glaxosmithkline, s.aServicio Murciano de Salud - Gerencia€26,655,490Awarded12 November 2026
EN La-ASP1-26-021. Contratación mediante Acuerdo Marco con varios empresarios de él suministro sucesivo de diversos medicamentos para él tratamiento de él mieloma múltiple para los centros hospitalarios de él Servicio Gallego de SaludConsellería de Sanidade- SERGAS—Awarded12 November 2026
Suministro de medicamentos para el Servicio de Farmacia del Hospital Universitario de Ceuta, mediante contrato basadoGerencia de Atención Sanitaria del Instituto Nacional de Gestión Sanitaria en Ceuta€200,485Awarded12 November 2026
Suministro sucesivo del medicamento "CILTACABTAGEN AUTOLEUCEL"Área Sanitaria da Coruña e Cee - Servicio Gallego de Salud€86,779,166Awarded12 November 2026
EN La-ASC1-26-062. Él suministro sucesivo de los medicamentos IDECABTAGEN VICLEUCEL y CILTACABTAGEN AUTOLEUCEL para los centros hospitalarios de él Servicio Gallego de SaludConsellería de Sanidade- SERGAS—Awarded12 November 2026
Tibsovo 250 mg comprimidos recubiertos con película, 60 comprimidosHospital Universitario Principe de Asturias€286,260Awarded11 November 2026
Rystiggo 140 mg/ml solución inyectable, 1 vial de 3 mlHospital Universitario Principe de Asturias€409,633Awarded11 November 2026
Suministro de medicamentos para el Servicio de Farmacia del Hospital Universitario de Ceuta, mediante contrato basadoGerencia de Atención Sanitaria del Instituto Nacional de Gestión Sanitaria en Ceuta€55,798Awarded11 November 2026
Suministro de medicamentos para el Servicio de Farmacia del Hospital Universitario de Ceuta, mediante contrato basado.Gerencia de Atención Sanitaria del Instituto Nacional de Gestión Sanitaria en Ceuta€132,688Awarded10 November 2026
EN La-ASP1-26-019. La contratación, mediante Acuerdo Marco con varios empresarios, de él suministro sucesivo de los medicamentos de inmunoterapia oncológica para los centros hospitalarios de él Servicio Gallego de SaludConsellería de Sanidade- SERGAS—Awarded9 November 2026
EN La-ASC1-26-061. Él suministro sucesivo de los medicamentos IDECABTAGEN VICLEUCEL y CILTACABTAGEN AUTOLEUCEL para los centros hospitalarios de él Servicio Gallego de SaludConsellería de Sanidade- SERGAS—Awarded6 November 2026

Competition and prices

In 2025, half of the contracts were worth between €8,200 and €260,000, with a median of €41,000 (284 contracts with a stated awarded value). Contracts drew 2.6 bids on average (median 3) and 32% drew a single bid — based on 328 contracts with a known number of bids. Compared with 2024, in 2025 the median value fell 66% and the share of single-bid contracts fell from 52% to 32%. The usual procedures: negotiation without a call for competition (43%), open procedure (29%), negotiated procedure (20%) — of 577 tenders with a stated procedure.

The most contracts went to Janssen Cilag, S.A. (128), PFIZER, S.L.U. (85) and Roche Farma, S.A. (84) — together 15% of all contracts.

YearContractsMedian valueMiddle half of valuesBids on averageSingle bid
2024869€120,000€19,000 – €820,0002.652% (285)
2025487€41,000€8,200 – €260,0002.632% (328)
2026 (so far)499€100,000€21,000 – €430,0002.870% (334)
All years1,932€100,000€15,000 – €650,0003.050% (992)

Values: contracts with a stated value in EUR, each value kind on its own (awarded or contract value), approximate (±3 %). Bids: contracts of procedures with competition whose number of bids the source publishes (1–100 bids); the sources publish it for some contracts only (TED ≈ 3 in 4, Spain all, Poland about half, Italy few), so each figure states its base and is shown from 20 contracts. A contract counts in the year of its award (else of its tender). Figures as of 13 November 2026, recomputed every week.

Where you have a chance

Since 1 November 2024, 50% of the 763 contracts with a known number of bids had a single bid; the median was 2 bids. The number of bids is known for 763 of the 787 contracts from procedures with competition.

Buyers who often get few offers

The buyers below usually received one or two offers per contract — an offer from you would stand out.

In the last 12 months, 3 companies won their first contract in our records here — 1% of the 473 contracts (our records start on 1 January 2024).

Contracts awarded since 1 November 2024 (the last 24 months). Bids as the source publishes them, 1 to 100 per contract, in procedures with competition only (a direct award has one offer by design). As of 13 November 2026.

Main CPV divisions

CPV codes of this topic

  • 33652000 Antineoplastic and immunomodulating agents

A tender belongs here when its main CPV code starts with one of these codes; a tender without a usable CPV code (or with a general one) is matched by words of its title. A tender may belong to up to three topics.

Oncology and immunomodulating drugs in neighbouring countries

Today, 1 tender in the same niche is open in neighbouring countries.

Public tenders in the EU and the EEA are open to companies from every EU and EEA country on the same terms as local ones, and to companies from countries with a procurement agreement with the EU (such as Switzerland, the United Kingdom and Ukraine) for the contracts it covers. Open means the deadline has not passed (today's date). Neighbours: countries with a land border, a fixed link or a short sea crossing.

Expected soon5

ExpectedBuyerWhatWhy we expect itConfidence
now – Mar 2027
contract ends
Servicio Madrileno de Salud, Hospital Universitario La PazOncology and immunomodulating drugs
SUMINISTRO DE MEDICAMENTOS EXCLUSIVOS: ERENUMAB (AIMOVIG), BACLOFENO (LIORESAL INTRATECAL), OCTEOTRIDO IM (SANDOSTATIN LAR), EVEROLIMUS INMUNOSUPRESOR (CERTICAN), RIBOCICLIB (KISQALI) Y LAPATINIB (TYVERB).
Typical value: ≈ €91,000
The current contract with NOVARTIS FARMACEUTICA, S.A. ends on 20 April 2027 (from its stated duration); no new tender has been published yet.
Earlier tenders: 07/2026
high
now – Dec 2026
contract ends
Servicio Madrileño de Salud - Hospital Universitario 12 de OctubreOncology and immunomodulating drugs
SUMINISTRO DE ANTINEOPLÁSICOS CON DESTINO AL SERVICIO DE FARMACIA DEL HOSPITAL UNIVERSITARIO 12 DE OCTUBRE
Typical value: ≈ €33,000
The current contract with PIERRE FABRE IBERICA S.A. ends on 12 January 2027 (from its stated duration); no new tender has been published yet.
Earlier tenders: 02/2024
medium
now – Dec 2026
contract ends
Corporació Sanitària Parc Taulí de SabadellOncology and immunomodulating drugs
SUBMINISTRAMENT FÀRMACS BIOSIMILARS I BIOLÒGICS
Typical value: ≈ €390,000
The current contract with ROCHE FARMA, SA ends on 31 December 2026; no new tender has been published yet. The current contract with ORGANON SALUD, S.L. ends on 31 December 2026; no new tender has been published yet. The current contract with KERN PHARMA, S.L. ends on 31 December 2026; no new tender has been published yet. The current contract with ROCHE FARMA, SA ends on 31 December 2026; no new tender has been published yet. The current contract with ALEXION PHARMA SPAIN, SL ends on 31 December 2026; no new tender has been published yet. The current contract with DAIICHI SANKYO ESPAÑA, S.A. ends on 31 December 2026; no new tender has been published yet.
Earlier tenders: 03/2024, 03/2024, 03/2024, 07/2024, 09/2024, 03/2025
high
Dec 2026 – May 2027
contract ends
Departamento de Salud Alcoy. Dirección Económica-GerenciaOncology and immunomodulating drugs
Suministro, respetuoso con el medio ambiente, de medicamentos de uso humano bilógicos con biosimilares destinado a los centros del ámbito de la sanidad pública valenciana
Typical value: ≈ €23m
The current contract with KERN PHARMA, S.L. ends on 4 June 2027 (from its stated duration); no new tender has been published yet.
Earlier tenders: 02/2024
high
Dec 2026 – May 2027
contract ends
Corporació de Salut del Maresme i la SelvaOncology and immunomodulating drugs
Adjudicación del Contrato Basado del Acuerdo Marco del Suministro de MEDICAMENTOS ONCOLÓGICOS de la Corporació de Salut del Maresme i la Selva
Typical value: ≈ €610,000
The current contract with ACCORD HEALTHCARE, SLU ends on 22 June 2027 (from its stated duration); no new tender has been published yet.
Earlier tenders: 06/2025
high

Forecast from public data, not an announcement. Methodology.

Market reports

Oncology and immunomodulating drugs by city

Oncology and immunomodulating drugs in other countries

Oncology and immunomodulating drugs across Europe

Topics in Health, medical equipment and medicines

Questions and answers

Which oncology drug tenders in Spain are open now?
2 of the 723 oncology drug tenders in Spain listed on GranTender are open for bids. For example: Suministro de Antineoplásicos Orales para el Servicio de Farmacia del Hospital Clínico San Carlos; SUMINISTRO DE ANTINEOPLÁSICOS ORALES CON DESTINO AL SERVICIO DE FARMACIA DEL HOSPITAL CLÍNICO SAN CARLOS.
Where can I find oncology drug tenders in Spain?
GranTender lists them in one place, from PLACSP, Registre públic de contractes de Catalunya (RPC) — Catalan public contracts register, open data (Generalitat) and TED, with their buyers, winners and contract values; 2 are open now. Search in one country at a time (the first 5 results) is free; search across all countries at once, full result lists, saved keywords with an e-mail once a week and exports come with a plan.
Who wins the most oncology drug tenders in Spain?
By number of contracts won: Janssen Cilag, S.A. (128), PFIZER, S.L.U. (85), Roche Farma, S.A. (84).
Which buyers publish the most oncology drug tenders in Spain?
By number of tenders: Consellería de Sanidade- SERGAS (114), Hospital Universitario Principe de Asturias (72), Gestió Pius Hospital de Valls, SAM (54).
Which CPV codes belong to “Oncology and immunomodulating drugs”?
33652000 Antineoplastic and immunomodulating agents; plus tenders without a usable CPV code whose title names the topic.
How many bids do oncology drug tenders in Spain receive on average?
In 2025, contracts drew 2.6 bids on average (median 3) and 32% drew a single bid — based on 328 contracts with a known number of bids.
How much are contracts for oncology drug tenders in Spain worth?
In 2025, half of the contracts were worth between €8,200 and €260,000, with a median of €41,000 (284 contracts with a stated awarded value). Compared with 2024, in 2025 the median value fell 66% and the share of single-bid contracts fell from 52% to 32%.
Which procedures are used for oncology drug tenders in Spain?
The usual procedures: negotiation without a call for competition (43%), open procedure (29%), negotiated procedure (20%) — of 577 tenders with a stated procedure.
Which buyers get few offers in oncology drug tenders in Spain?
Since 1 November 2024, these buyers usually received one or two offers per contract: Consellería de Sanidade- SERGAS (median 1 bid over 154 contracts), Servicio Cántabro de Salud (median 1 bid over 97 contracts) and Gerencia de Atención Primaria del Area de Salud de Tenerife (median 1 bid over 24 contracts). Since 1 November 2024, 50% of the 763 contracts with a known number of bids had a single bid; the median was 2 bids.

CPV 2008 (Regulation (EC) No 213/2008), © European Union, Publications Office — via the eForms SDK, CC BY 4.0.